Commentary: bias among Patient representatives on FDA panels questioned
This article was originally published in Scrip
Executive Summary
The US FDA has frequently faced criticism that it has not done enough to screen advisory panel members for potential pro-industry biases, or that it "stacked the deck" with experts who are unlikely to be critical of a new drug under review.